HIV Prevention and Alcohol (R34 Clinical Trials Optional)
ID: 348090Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348090

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAS-23-172.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "HIV Prevention and Alcohol (R34 Clinical Trials Optional)" aimed at enhancing HIV/AIDS prevention strategies among populations impacted by alcohol use. This initiative invites proposals for planning grants that focus on innovative research to inform the design of clinical trials testing the efficacy and safety of interventions for HIV prevention among alcohol-using individuals, particularly targeting high-risk groups such as men who have sex with men and transgender individuals. The NIH emphasizes the importance of addressing critical barriers to HIV prevention through advanced methodologies, including modern technology and mobile health initiatives. The total funding available is approximately $1.5 million, with individual awards reaching up to $450,000 over three years. Interested applicants must adhere to strict application guidelines and submit their proposals by May 7, 2026, with further inquiries directed to grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAS-23-172-Full-Announcement.html
    PAS-23-172.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity titled "HIV Prevention and Alcohol (R34 Clinical Trials Optional)" aimed at enhancing HIV/AIDS prevention strategies among populations affected by alcohol use. This opportunity invites planning grant proposals focusing on innovative research that can inform the design of clinical trials aimed at testing the efficacy and safety of interventions for HIV prevention among alcohol-using individuals. The initiative supports studies that address critical barriers to HIV prevention, particularly regarding high-risk groups, such as men who have sex with men, transgender individuals, and other marginalized populations. Proposals should incorporate advanced methodologies, including the utilization of modern technology for data collection and new intervention strategies like mobile health (mHealth) initiatives. Funding totals approximately $1.5 million, with individual award budgets reaching up to $450,000 over three years. All applications must comply with stringent application guidelines and undergo a rigorous peer review process. This opportunity underscores the NIH's commitment to addressing the intersection of alcohol use and HIV prevention, responding to public health challenges within diverse communities.
    Similar Opportunities
    HIV Prevention and Alcohol (R01 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HIV Prevention and Alcohol (R01 Clinical Trials Optional)" aimed at expanding HIV prevention strategies among populations affected by alcohol use. This initiative encourages research projects that explore the relationship between alcohol consumption and HIV risk behaviors, focusing on areas such as Pre-exposure Prophylaxis (PrEP) utilization, Treatment as Prevention (TasP), and the integration of preventive intervention strategies. The program is particularly significant for addressing health disparities among high-risk groups, including men who have sex with men (MSM) and women with high-risk partners. The NIH anticipates funding between $2 million for 2 to 4 awards, with a project period of up to five years. Interested applicants can submit their proposals through the NIH ASSIST system or Grants.gov, and should direct inquiries to grantsinfo@nih.gov. The application deadline is May 7, 2026.
    Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity (PA-21-205) aimed at the development and testing of innovative interventions to enhance HIV prevention, treatment, and program implementation for individuals who use drugs. This R34 grant focuses on formative research and pilot studies that assess the feasibility, safety, and acceptability of various interventions, including behavioral, social, and structural approaches, particularly integrating substance use considerations into HIV care. The initiative is crucial in addressing the ongoing challenges of the HIV epidemic among populations significantly impacted by substance use, with projects expected to enhance HIV testing, preventive services, and treatment adherence. Interested applicants can apply for grants with a ceiling of $225,000, and the application deadline is January 7, 2025. For further information, contact the NIH OER Webmaster at grantsinfo@nih.gov or visit the funding announcement at http://grants.nih.gov/grants/guide/pa-files/PA-21-205.html.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research to enhance the integration of HIV, addiction, and primary care services. This initiative invites applications for R34 Planning Grants to develop and test models that improve healthcare delivery for individuals at risk for or living with HIV, Hepatitis B and C, and substance use disorders, with a focus on strategies such as integrating substance misuse prevention within HIV care settings. The total funding available for this project is $2 million, with awards potentially lasting up to three years, and applications are due by March 20, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research in integrated care models for HIV/AIDS and substance use disorders. The initiative seeks to improve health outcomes and enhance care coordination for individuals at heightened risk by addressing service delivery gaps through collaborative and evidence-based practices. This grant, with a funding ceiling of $450,000 over three years, is open to a diverse range of eligible applicants, including higher education institutions and community-based organizations, with applications due by March 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-020.html.
    Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)." This initiative aims to support formative research and pilot-testing of interventions designed to enhance HIV prevention and treatment outcomes, particularly focusing on innovative strategies that address mental health, social determinants, and structural factors affecting HIV care. The funding opportunity is crucial for developing effective HIV testing and treatment linkage strategies, ultimately contributing to national goals in HIV management and reducing health disparities among affected populations. Eligible applicants can receive direct costs up to $225,000 per year for a project duration not exceeding three years, with applications due by January 9, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-060.html.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional)." This initiative aims to support the development and testing of innovative care models that integrate HIV, addiction, and primary care services to improve health outcomes, particularly for individuals at heightened risk of HIV and those living with HIV alongside substance use disorders. The program is part of the broader "Ending the HIV Epidemic" plan, emphasizing the need for coordinated and scalable service models that address barriers to care and social determinants of health. Interested applicants can apply for grants with an award ceiling of $459,000, with submissions due by March 19, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-059.html.
    Alcohol Health Services Research (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Alcohol Abuse and Alcoholism (NIAAA), has announced a funding opportunity titled "Alcohol Health Services Research (R34 Clinical Trial Optional)" (PAR-23-252). This initiative aims to address the treatment gap for individuals with Alcohol Use Disorder (AUD) by focusing on improving access to treatment, reducing stigma, examining cost structures, and implementing evidence-based approaches, particularly for health disparity populations. The total project budget is capped at $450,000 over a three-year period, and eligible applicants include higher education institutions, nonprofits, and government agencies, with a specific emphasis on those serving underrepresented communities. Interested parties should submit their applications electronically by October 16, 2023, with funding available until September 8, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.